Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GPR119 | Q8TDV5 | 9/20 | 0.34 |
| ▸ | NR1H2 | P55055 | 3/20 | 0.33 |
| ▸ | ABCB1 | P08183 | 1/20 | 0.33 |
| ▸ | HSD11B1 | P28845 | 1/20 | 0.32 |
| ▸ | NR1H3 | Q13133 | 2/20 | 0.32 |
| ▸ | PARP1 | P09874 | 1/20 | 0.31 |
| ▸ | HCRTR2 | O43614 | 1/20 | 0.31 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2080999 | 1.00 | GPR119 (0.34) | GPR119NR1H2ABCB1HSD11B1NR1H3 | |
| SCHEMBL2200885 | 1.00 | GPR119 (0.34) | GPR119NR1H2ABCB1HSD11B1NR1H3 | |
| SCHEMBL8690955 | 1.00 | GPR119 (0.34) | GPR119NR1H2ABCB1HSD11B1NR1H3 | |
| SCHEMBL1526484 | 0.87 | NR1H2 (0.35) | NR1H2ABCB1PARP1 | |
| SCHEMBL4560424 | 0.87 | PPM1D (0.32) | — | |
| SCHEMBL24894673 | 0.87 | NR1H2 (0.35) | GPR119NR1H2ABCB1PARP1 | |
| SCHEMBL9383410 | 0.87 | NR1H2 (0.35) | GPR119NR1H2ABCB1PARP1 | |
| SCHEMBL1526483 | 0.87 | NR1H2 (0.35) | NR1H2ABCB1PARP1 | |
| SCHEMBL24826386 | 0.87 | NR1H2 (0.35) | GPR119NR1H2ABCB1PARP1 | |
| SCHEMBL2387181 | 0.87 | NR1H2 (0.35) | GPR119NR1H2ABCB1PARP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 21 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20170022201-A1 | MACROCYLIC PYRIDINE DERIVATIVES | JANSSEN PHARMACEUTICA NV (BE) | 2017-01-26 | — | — | US | disclosed |
| US-20170022201-A1 | MACROCYLIC PYRIDINE DERIVATIVES | JANSSEN PHARMACEUTICA NV (BE) | 2017-01-26 | — | — | US | disclosed |
| US-9546173-B2 | Substituted pyrrolo[3,4-d]pyrimidines as kinase inhibitors | NOVARTIS AG (CH) | 2017-01-17 | — | — | US | disclosed |
| EP-2897961-B1 | DIHYDROPYRROLIDINO-PYRIMIDINES AS KINASE INHIBITORS | NOVARTIS AG (CH) | 2016-10-26 | — | — | EP | disclosed |
| WO-2015150557-A1 | MACROCYLIC PYRIDINE DERIVATIVES | JANSSEN PHARMACEUTICA NV (BE) | 2015-10-08 | — | — | WO | disclosed |
| US-20150274733-A1 | DIHYDROPYRROLIDINO-PYRIMIDINES AS KINASE INHIBITORS | NOVARTIS AG (CH) | 2015-10-01 | — | — | US | disclosed |
| EP-2897961-A1 | DIHYDROPYRROLIDINO-PYRIMIDINES AS KINASE INHIBITORS | Novartis AG (CH) | 2015-07-29 | — | — | EP | disclosed |
| WO-2014047020-A1 | DIHYDROPYRROLIDINO-PYRIMIDINES AS KINASE INHIBITORS | NOVARTIS AG (CH) | 2014-03-27 | — | — | WO | disclosed |
| US-20070117986-A1 | TRANS-3,5-DISUBSTITUTEDPYRROLIDINE: ORGANOCATALYST FOR anti-MANNICH REACTIONS | THE SCRIPPS RESEARCH INSTITUTE | 2007-05-24 | — | — | US | disclosed |
| EP-1019529-A4 | A METHOD OF TREATING CANCER | MERCK & CO INC (US) | 2002-09-11 | — | — | EP | disclosed |
| EP-1019530-A1 | A METHOD OF TREATING CANCER | Merck & Co., Inc. (US) | 2000-07-19 | — | — | EP | disclosed |
| EP-1019529-A1 | A METHOD OF TREATING CANCER | Merck & Co., Inc. (US) | 2000-07-19 | — | — | EP | disclosed |
| WO-2000016626-A1 | A METHOD OF TREATING CANCER | MERCK & CO., INC. (US) | 2000-03-30 | — | — | WO | disclosed |
| US-5972984-A | LOW MOLECULAR WEIGHT PEPTIDYL COMPOUNDS THAT DO NOT HAVE A THIOL MOIETY. | MERCK & CO., INC. (US) | 1999-10-26 | — | — | US | disclosed |
| EP-0833633-A4 | INHIBITORS OF FARNESYL-PROTEIN TRANSFERASE | MERCK & CO INC (US) | 1999-03-24 | — | — | EP | disclosed |
| WO-1999010524-A1 | A METHOD OF TREATING CANCER | MERCK & CO., INC. (US) | 1999-03-04 | — | — | WO | disclosed |
| WO-1999010525-A1 | A METHOD OF TREATING CANCER | MERCK & CO., INC. (US) | 1999-03-04 | — | — | WO | disclosed |
| US-5756528-A | ANTICARCINOGENIC AGENTS | MERCK & CO., INC. (US) | 1998-05-26 | — | — | US | disclosed |
| EP-0833633-A1 | INHIBITORS OF FARNESYL-PROTEIN TRANSFERASE | Merck & Co., Inc. (US) | 1998-04-08 | — | — | EP | disclosed |
| WO-1996039137-A1 | INHIBITORS OF FARNESYL-PROTEIN TRANSFERASE | MERCK & CO., INC. (US) | 1996-12-12 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170022201-A1 | MACROCYLIC PYRIDINE DERIVATIVES | VPS26B, VPS4B, VPS28 | GPR119 1464/4885NR1H2 4254/4885ABCB1 587/4885 |
| US-20070117986-A1 | TRANS-3,5-DISUBSTITUTEDPYRROLIDINE: ORGANOCATALYST FOR anti-MANNICH REACTIONS | HRH4, NR1I3, NR1I2 | GPR119 2137/4885NR1H2 14/4885ABCB1 1649/4885 |
| US-20150274733-A1 | DIHYDROPYRROLIDINO-PYRIMIDINES AS KINASE INHIBITORS | MAP3K1, MAP3K2, BRAF | GPR119 1763/4885NR1H2 1113/4885ABCB1 680/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.